NeoChord
Cardiovascular Devices
$89.5Mtotal raised · 11 rounds on record
$493klatest round · Convertible Note · Feb 2025 · 20 mo ago
1backers · USVP
12team · US Form 5500 (plan participants) · Dec 2025 · -8% in a year
Overview
Direct Repair On A Beating Heart The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients wit ...
Key facts
These are the key facts about NeoChord on Alion as of Nov 13, 2026. NeoChord is headquartered in St. Louis Park, United States. It has raised $89.5M in 11 funding rounds. The latest round is Convertible Note of $493k, announced in 2025.
- Headquarters
- St. Louis Park, United StatesAlion company profile, updated Oct 11, 2026
- Employees
- 200+Alion company profile, an estimated range
- Total raised
- $89.5MSum of 11 equity rounds Alion knows
- Latest round
- Convertible Note · $493k · Feb 27, 2025SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$89.5M
11 rounds on record
Latest round
$493k
Convertible Note · Feb 2025 · 20 mo ago
Team
12
US Form 5500 (plan participants) · Dec 2025 · -8% in a year
Backers
1
USVP
The money's age
Due for its next round
20 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 27, 2025
Raised a round Convertible Note $493k · SEC Form D
Aug 16, 2024
Raised a round Convertible Note $914k · SEC Form D
Feb 22, 2024
New executive NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitati… · PRNewswire
Jun 20, 2023
Raised a round Convertible Note $4.6M · SEC Form D
Sep 8, 2022
Raised a round Convertible Note $2.9M · SEC Form D
Feb 23, 2022
Raised a round Convertible Note $1.8M · SEC Form D
Sep 10, 2021
Raised a round Convertible Note $1M · SEC Form D
Apr 27, 2021
Raised a round Convertible Note $2.8M · SEC Form D
Nov 6, 2018
Raised a round Series D $25M
Sep 1, 2017
Raised a round Convertible Note $4M · SEC Form D
May 12, 2016
Certified NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation · businesswire.com
Oct 20, 2015
New executive NeoChord Appoints Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality · businesswire.com
May 22, 2015
Raised a round Venture round $12.6M · MedCity News
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Convertible Note | Feb 2025 | $493k | — | SEC Form D |
| Convertible Note | Aug 2024 | $914k | — | SEC Form D |
| Convertible Note | Jun 2023 | $4.6M | — | SEC Form D |
| Convertible Note | Sep 2022 | $2.9M | — | SEC Form D |
| Convertible Note | Feb 2022 | $1.8M | — | SEC Form D |
| Convertible Note | Sep 2021 | $1M | — | SEC Form D |
| Convertible Note | Apr 2021 | $2.8M | — | SEC Form D |
| Series D | Nov 2018 | $25M | — | neochord.com |
| Venture round | Oct 2018 | $33.4M | — | SEC Form D |
| Convertible Note | Sep 2017 | $4M | — | SEC Form D |
| Venture round | May 2015 | $12.6M | — | MedCity News |
Registers and programsofficial lists and records that name the company
| Legal entity | NEOCHORD INC | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Ron NelsonExecutive OfficerSEC Form D
David ChungExecutive Officer, DirectorSEC Form D
Todd BergExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Developing the next generation of left-heart access technologies.
Replacing Hearts. Restoring Lives. HEART FAILURE Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2…
Ceryx Medical is developing Cysoni, an implantable pacemaker that restores heart–lung synchronisation in heart failure patients who have no…
Pacertool develops PaCRTool, a highly differentiated and proprietary solution to improve cardiac resynchronization therapy (CRT) in heart…
Innovating a Better Way. CroíValve’s mission is to help patients suffering from tricuspid regurgitation with a new, minimally invasive…
Redefining mitral valve repair with CARLEN — a single-leaflet solution expanding options for TEER-eligible and previously untreatable…
Financials
Total raised
$89.5M
Latest round
Convertible Note
Funding rounds
11
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Convertible Note | 2025 | $493k | Details |
| Convertible Note | 2024 | $914k | Details |
| Convertible Note | 2023 | $4.6M | Details |
| Convertible Note | 2022 | $2.9M | Details |
| Convertible Note | 2022 | $1.8M | Details |
| Convertible Note | 2021 | $1M | Details |
| Convertible Note | 2021 | $2.8M | Details |
| Series D | 2018 | $25M | Details |
| Venture - Series Unknown | 2018 | $33.4M | Details |
| Convertible Note | 2017 | $4M | Details |
| Venture - Series Unknown | 2015 | $12.6M | Details |
People
Ron Nelson
Executive Officer
David Chung
Executive Officer, Director
Todd Berg
Executive Officer, Director
J. Martin
Director
Nicole Walker
Director
Andrew ElBardissi
Director
Michael Fulton
Director
Casey Tansey
Director
Mudit Jain
Director
Michael Liang
Director
David Gregorka
Director
David Neustaedter
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
USVPVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation
/PRNewswire/ -- NeoChord is a privately held, medical technology company and the world-leader in beating heart delivery of artificial chords in the treatment...
Read more
Report
NeoChord Announces $25 Million Series D Financing to Accelerate Development of Two Transcatheter Chordal Repair Programs
November 2018 CLICK FOR RELEASE
Read more
Report
NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation
Read more
Report
NeoChord Appoints Lori Adels, Ph.D. as Vice President of Clinical Affairs, Regulatory and Quality
Read more
Report
NeoChord gets $12.6M for mitral valve repair tool that works without stopping the heart
NeoChord's aim is to cut down the invasiveness of mitral valve repair surgery, and just raised $12.6 million to do so.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
St. Louis Park
United States
HQ
200-500 est. staff
How to cite this page
Alion, "NeoChord: key facts", as of Nov 13, 2026. https://alion.io/company/neochord
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0